Literature DB >> 21332688

Enfuvirtide injection site reactions: a clinical and histopathological appraisal.

Brian J Wallace1, King-Bing Tan, Sarah L Pett, David A Cooper, Steven Kossard, Margot J Whitfeld.   

Abstract

BACKGROUND/
OBJECTIVES: Enfuvirtide was the first of a new class of antiretroviral agents termed 'fusion inhibitors' used for the treatment of HIV-1 infection. Enfuvirtide is administered subcutaneously and injection site reactions (ISR) are commonplace (98%). The aim of this study was to analyse in detail the histopathological changes associated with striking ISR seen in four patients.
METHODS: Biopsies were obtained at various times post-injection and were reviewed histologically. The changes in epidermal, dermal and subcutaneous connective tissue and the presence and nature of the inflammatory cellular infiltrate were noted. An immunohistochemical assessment was undertaken.
RESULTS: All biopsy specimens demonstrated striking changes in the dermal connective tissue. Alteration in collagen was the most prominent feature and resembled a morphoea/scleroderma-like process. These changes persisted well beyond cessation of enfuvirtide (>1 year). The relative populations of dermal dendritic cells (DDC) (types 1 (Factor XIIIa) and 2 (CD34+)) were analysed and a reciprocal relationship between DDC subpopulations was observed akin to that observed in other sclerosing and fibrosing conditions.
CONCLUSION: This study details histopathological changes associated with enfuvirtide ISR. We postulate that changes in DDC populations may contribute to the pathogenesis of the sclerotic process observed with enfuvirtide ISR.
© 2011 The Authors. Australasian Journal of Dermatology © 2011 The Australasian College of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21332688     DOI: 10.1111/j.1440-0960.2010.00717.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  5 in total

1.  Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration.

Authors:  Anita D'Souza; Jason D Theis; Julie A Vrana; Ahmet Dogan
Journal:  Amyloid       Date:  2014-01-22       Impact factor: 7.141

2.  Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.

Authors:  Arangassery Rosemary Bastian; Aakansha Nangarlia; Lauren D Bailey; Andrew Holmes; R Venkat Kalyana Sundaram; Charles Ang; Diogo R M Moreira; Kevin Freedman; Caitlin Duffy; Mark Contarino; Cameron Abrams; Michael Root; Irwin Chaiken
Journal:  J Biol Chem       Date:  2014-11-04       Impact factor: 5.157

3.  Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions.

Authors:  Arangassery Rosemary Bastian; Mark Contarino; Lauren D Bailey; Rachna Aneja; Diogo Rodrigo Magalhaes Moreira; Kevin Freedman; Karyn McFadden; Caitlin Duffy; Ali Emileh; George Leslie; Jeffrey M Jacobson; James A Hoxie; Irwin Chaiken
Journal:  Retrovirology       Date:  2013-12-13       Impact factor: 4.602

Review 4.  The Emerging Roles of Silver Nanoparticles to Target Viral Life Cycle and Detect Viral Pathogens.

Authors:  Ujjyani Ghosh; Khondakar Sayef Ahammed; Snehasis Mishra; Asim Bhaumik
Journal:  Chem Asian J       Date:  2022-01-24

Review 5.  HIV-Associated Systemic Sclerosis: Literature Review and a Rare Case Report.

Authors:  Shamimul Hasan; Mohd Aqil; Rajat Panigrahi
Journal:  Int J Environ Res Public Health       Date:  2022-08-15       Impact factor: 4.614

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.